Answering Your Questions about Parkinson’s disease and Coronavirus Disease 2019 (COVID-19)

Answering Your Questions about Parkinson’s disease and Coronavirus Disease 2019 (COVID-19) – Updated With the continued spread of Coronavirus Disease 2019, also known as COVID-19, in the United States and throughout the world, Parkinson’s disease (PD) patients have been reaching out and asking questions and we’re here with the answers you need. As such, we […]

Read More

The FDA approves F-Dopa PET imaging to aid in early diagnosis of Parkinson’s disease

The FDA approves F-Dopa PET imaging to aid in early diagnosis of Parkinson’s disease The FDA recently approved Flourodopa F18 (F-Dopa), a radioactive tracer for positron emission tomography (PET) that can help visualize the nerve endings of dopaminergic neurons. It can be used to help in the diagnosis of Parkinson’s disease (PD) and other parkinsonian […]

Read More

Promising results from the University of Pittsburgh APDA Center for Advanced Research

Promising results from the University of Pittsburgh APDA Center for Advanced Research Building off of pivotal APDA-funded work highlighted here, Dr. J. Timothy Greenamyre and his team, published a new study  investigating the role of Leucine-rich Repeat Kinase (LRRK2) in the development of Parkinson’s disease (PD). LRRK2 is known to be mutated in a small […]

Read More

Taking Parkinson’s education to the farmers market: educating under-served communities

Taking Parkinson’s education to the farmers market: educating under-served communities Dr. Lynda Nwabuobi, Movement Disorder Fellow at Columbia Presbyterian Medical Center in New York City, attended APDA’s Diversity in Parkinson’s Disease (PD) Research Conference in May and was inspired. Dr. Nwabuobi  had just spent the day learning about health care disparities in PD care, low […]

Read More

APDA ANNOUNCES $1.7 MILLION IN NEW PARKINSON’S DISEASE RESEARCH GRANTS. FUNDING ENABLES 10 RESEARCHERS TO CONDUCT IMPACTFUL RESEARCH.

APDA announces funding for 2019-2020 grants It is that time of year – when APDA announces our research grantees for the 2019-2020 fiscal year. We are very proud of our grant recipients who each has a unique idea that will hopefully benefit the entire Parkinson’s disease (PD) community. This year APDA has awarded $1.7 million […]

Read More

New medication, Istradefylline, gets approved for Parkinson’s disease

New medication, Istradefylline, gets approved for Parkinson’s disease On August 27, 2019, pharmaceutical company Kyowa Kirin received FDA approval for Istradefylline, a new medication for Parkinson’s disease (PD) to be used as an add-on treatment to carbidopa/levodopa for those experiencing OFF episodes. (For more information on OFF periods in PD, please see this recent APDA […]

Read More